Novavax Inc had announced that NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine, demonstrated 100 per cent protection against moderate and severe disease, 90.4 per cent efficacy overall.
The Drug Controller General of India (DCGI) on Friday granted Serum Institute of India (SII) the permission to manufacture Russian COVID Vaccine- Sputnik V for examination test and analysis at its licensed facility at Hadapsar, ANI quoted sources as saying.
London: Admitting that he is facing immense pressure from “some of the most powerful people in India” demanding supplies of Covishield, Serum Institute of India (SII) CEO Adar Poonawalla said on…
New Delhi: Serum Institute of India (SII) — the maker of the most used COVID-19 vaccine in the country — on Wednesday announced a cut in price of the jab…
Bhubaneswar: Odisha Chief Minister Naveen Patnaik talked to Adar Poonawalla, CEO of Serum Institute over a video call today to discuss on progress of Covid vaccine. The Chief Minister expressed happiness that Serum Institute has partnered with Oxford University to develop Covid vaccine and sought his cooperation to begin early vaccination in Odisha once necessary […]
New Delhi: Five sites across the country are ready for the third and final phase of human trials of the Oxford-AstraZeneca COVID-19 vaccine, Department of Biotechnology (DBT) Secretary Renu Swarup said on Monday. This is an essential step because it is necessary to have data within the country before the vaccine is administered to Indians, […]
New Delhi: The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed COVID-19 vaccine candidate in the country. Government officials told PTI that the approval for conducting phase 2 and 3 clinical trials by […]
New Delhi: Serum Institute of India (SII), the worlds largest vaccine manufacturer by volume, has entered into a new landmark partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries […]
New Delhi: The central drug regulator has issued a show-cause notice to the Serum Institute of India (SII) for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine candidate for COVID-19 in other countries and also for not submitting casualty analysis of the “reported serious adverse events”. The show-cause […]
New Delhi: The Serum Institute of India (SII), which was conducting the India trials for the coronavirus vaccine being developed by Oxford University, on Thursday paused the clinical trials of the vaccine in India. In a statement, the Serum Institute of India said: “We are reviewing the situation and pausing India trials till AstraZeneca restarts […]
New Delhi: Drugs Controller General of India (DCGI) Dr V G Somani has gave permission to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial. The DCGI has, however, put certain […]
Pune: Adar Poonawalla, Chief Executive Officer of Serum Institute of India (SII) which is producing the potential coronavirus vaccine developed by Oxford University, asked on Saturday if the government will have Rs 80,000 crore available to buy and distribute the vaccine. “Quick question; will the government of India have 80,000 crores available, over the next […]
New Delhi: A further collaboration among the Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries. This brings the […]
New Delhi: After a Chennai-based volunteer served a legal notice to the Serum Institute of India (SII) demanding Rs 5 crore compensation for the alleged neurological complications he developed after being administered a test dose of its Covidshield vaccine, the SII has now countered the allegation with a demand of Rs 100 crore as damages […]
New Delhi: Serum Institute of India (SII) has applied for emergency use authorization of the first Made in India Covid-19 vaccine, Covishield. “As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorisation for the first made-in-India vaccine, COVISHIELD. This will save countless lives, and I thank the Government of India and […]
Copyright © 2024 - Odisha Television Limited All Rights Reserved.
LIVE TV
